NICE's severity modifiers misalign with public preferences in England & Wales, prioritising health gains at lower disease ...

To help inform the current debate on assisted dying, we have updated the findings of our 2019 palliative report with the ...

For the growing number of multi-indication medicines, challenges arise in assessing and paying for value across medicine indications with a uniform price (see our previous report and further ...

Bhaven N. Sampat is an economist by training, a Professor at the Department of Health Policy and Management at Columbia University, and a Research Associate at the National Bureau of Economic Research ...

This blog by Martina Garau (OHE) and Dr. Tina Wang (CIRS) provides a framework to navigate key aims, challenges and opportunities offered by recent initiatives and reflects on future prospects.

Ting (Tina) Wang is Associate Director, HTA Programme and Strategic Partnerships at the Centre for Innovation in Regulatory Science (CIRS). Tina leads CIRS’ work on HTA strategy and research as part ...

Oriol has built a career in the planning, policy and decision-making environment, participating not just in the micro management, but also being deeply involved on the meso and macro policy areas.

Should Health Technology Assessment Include the Bereavement Effect on Health-Related Quality of Life? What Difference Could It Make to Decisions About Life-Extending Treatments? Chris Skedgel ...

Siva is chief analyst in the policy team, leading on projects covering NHS funding, finances, productivity and performance. Before joining the Fund in 2017, Siva was head of analysis at NHS Providers ...

Ellie is on the fellowship programme with City University, studying Economic Evaluation in Healthcare. She has a BSc in Biochemistry from the University of Bath and worked in the pharmaceutical ...

Koonal is an associate director in the Science Policy and Research team at the National Institute for Health and Care Excellence. His project portfolio includes overseeing the NICE Listens ...